Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Opiate Modulation of Feeding

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04342130
Recruitment Status : Completed
First Posted : April 10, 2020
Last Update Posted : April 13, 2020
Sponsor:
Information provided by (Responsible Party):
Paul Geha, University of Rochester

Brief Summary:
This study will look at the short-term effect of morphine on brain response to food.

Condition or disease Intervention/treatment Phase
Chronic Low-back Pain Drug: Morphine Phase 4

Detailed Description:
Chronic low back pain patients and healthy controls will be recruited for this study. Participants' brain will be scanned at baseline and then again on a different day after the administration of an oral dose of 30 mg morphine in an open label design. Participants will receive morphine 60 minutes prior to the start of the second scanning session. The brain scans will include structural scans, functional scans at rest and functional scans during the ingestion of a highly caloric drink.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Opiate Modulation of Feeding
Actual Study Start Date : April 27, 2018
Actual Primary Completion Date : April 16, 2019
Actual Study Completion Date : April 16, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Back Pain

Arm Intervention/treatment
Experimental: All Participants
People with low back pain who were given and oral dose of 30 mg morphine.
Drug: Morphine
30 mg oral tablet




Primary Outcome Measures :
  1. mean change in subcortical brain structure volume [ Time Frame: baseline to 1 hour ]
    Magnetic Resonance Imaging (MRI) scanning was performed to collect brain volume measurements in cc.

  2. mean change in brain response to highly caloric drink [ Time Frame: baseline to 1 hour ]
    Participants received a highly caloric drink and a tasteless solution during a functional MRI scanning session. General linear model was used to generate the magnitude of the fit for each type of stimuli and differences between the fits were calculated. Next within subject analysis approach was used to calculate the effect of an acute dose of morphine on brain response to the highly caloric drink between baseline and 1 hour. The measures of the fit and their differences are expressed in z-scores.

  3. mean change in resting brain activity [ Time Frame: baseline to 1 hour ]
    Participants were scanned at rest during a functional MRI session.


Secondary Outcome Measures :
  1. mean change in back pain intensity [ Time Frame: baseline to 1 hour ]
    Pain was rated using a visual analog scale ranging from 0-100 with 100 indicating the worst imaginable pain ever.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy participants
  • Patients in pain: suffering from persistent pain more days than not, 3/10 in intensity on a numerical rating scale, for at least 6 weeks or more.

Exclusion Criteria:

  • Any DSM diagnosis
  • diabetes
  • food allergies
  • lactose intolerance
  • participants seeking to quit smoking or to lose weight
  • participants on any psychotropic medication including opiate based analgesics (e.g. oxycodone, methadone, suboxone)
  • pregnant or nursing women
  • pacemaker or other implanted electrical devices
  • Participants with a past history of head trauma or seizures
  • Any past history of illegal drug or alcohol misuse
  • Participants who cannot undergo an MRI scan.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04342130


Locations
Layout table for location information
United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
University of Rochester
Investigators
Layout table for investigator information
Principal Investigator: Paul Geha, MD Department of Psychiatry in University of Rochester
Layout table for additonal information
Responsible Party: Paul Geha, Assistant Professor, University of Rochester
ClinicalTrials.gov Identifier: NCT04342130    
Other Study ID Numbers: YaleIRB#1607018141
First Posted: April 10, 2020    Key Record Dates
Last Update Posted: April 13, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data available from this trial will made available to researcher via reasonable request from the PI.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: study protocol and analytic code will be available after manuscript publication
Access Criteria: Upon reasonable request from the PI

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Low Back Pain
Back Pain
Pain
Neurologic Manifestations
Morphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents